| You are here: Home: BCU 3|2002: David W Miles, MD: Select publications
select publications
capecitabine alone or in combination with other chemotherapeutic agents
Crown J. Nonanthracycline containing docetaxel-based combinations in metastatic breast cancer. Oncologist 2001;6(suppl 3):17-21. Abstract
Cunningham D, Coleman R. New options for outpatient chemotherapy - The role of oral fluoropyrimidines. Cancer Treat Rev 2001;27(4):211-20. Abstract
Domenech G et al. Vinorelbine/Capecitabine (VINOCAP) combination remission induction therapy for metastatic breast cancer (MBC). Proc ASCO 2001;Abstract 1939.
Fujimoto-Ouchi K et al. Schedule dependency of antitumor activity in combination therapy with capecitabine/5’-deoxy-5-fluorouridine and docetaxel in breast cancer models. Clin Cancer Res 2001;7(4):1079-1086. Abstract
Hori T et al. A randomized study comparing oral and standard regimens for metastatic breast cancer. Oncol Rep 2001;8(5):1067-71. Abstract
Kuhn JG. Fluorouracil and the new oral fluorinated pyrimidines. Ann Pharmacother 2001;35(2):217-27. Abstract
Leonard RC. Oral fluoropyrimidines among the new drugs for patients with metastatic breast cancer. Br J Cancer 2002;2(4):287-93. Abstract
Maher JF, Villalona-Calero MA. Taxanes and capecitabine in combination: Rationale and clinical results. J Clin Oncol 2001;35(2):217-27. Abstract
Michaud LB et al. Improved therapeutic index with lower-dose capecitabine in metastatic breast cancer (MBC) patients (Pts). Proc ASCO 2000;Abstract 402.
O’Shaughnessy JA et al. A retrospective evaluation of the impact of dose reduction in patients treated with Xeloda (capecitabine). Proc ASCO 2000;Abstract 400.
O’Shaughnessy JA et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 2001;12(9):1247-54. Abstract
Reigner B et al. Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 2001;40(2):85-104. Abstract
Schilsky RL. Pharmacology and clinical status of capecitabine. Oncology (Huntingt) 2000 Sep;14(9):1297-306; discussion 1309-11. Abstract
Thuss-Patience PC et al. Capecitabine: A new standard in metastatic breast cancer recurring after anthracycline and taxane-containing chemotherapy? Results of a multicenter phase II trial. Proc ASCO 2001;Abstract 2012.
Twelves C. Vision of the future: Capecitabine. Oncologist 2001;6(suppl 4):35-39. Abstract
Wang ML et al. Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancer. Am J Clin Oncol 2001;24(4):421-4. Abstract
|
